Clinical Trial

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated December 27, 2023 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05991206
Lead Sponsor Hunan Province Tumor Hospital
Conditions NSCLC
Enrollment 200 participants
Start Date 2023-12-25
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2023-12-27